Search results
Gevo Q2 Earnings Call Highlights
Key Points
- Interested in Gevo, Inc.? Here are five stocks we like better.
- Gevo raised its 2026 adjusted EBITDA outlook to more than $60 million, up from $30 million, supported by Canadian
Marathon Digital Q2 Earnings Call Highlights
Key Points
- Interested in Marathon Digital Holdings, Inc.? Here are five stocks we like better.
- MARA is pivoting toward AI infrastructure by leveraging its power, land and data-center assets
El Pollo Loco Q2 Earnings Call Highlights
Key Points
- Interested in El Pollo Loco Holdings, Inc.? Here are five stocks we like better.
- El Pollo Loco raised its 2026 outlook after second-quarter revenue increased to $129.6 million and
OmniAb Q2 Earnings Call Highlights
OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and
Insight Enterprises Q2 Earnings Call Highlights
Insight Enterprises (NASDAQ:NSIT) reported second-quarter results that exceeded its expectations, with broad-based growth in hardware, cloud and
PENN Entertainment Q2 Earnings Call Highlights
PENN Entertainment (NASDAQ:PENN) reported record second-quarter retail revenue and raised its full-year outlook for the segment
PDF Solutions Q2 Earnings Call Highlights
PDF Solutions (NASDAQ:PDFS) reported second-quarter revenue growth of 19% from a year earlier and reaffirmed its expectation for 20% revenue
Open Text Q4 Earnings Call Highlights
Open Text (NASDAQ:OTEX) reported fourth-quarter fiscal 2026 revenue growth in constant currency, led by its core cloud portfolio
Omada Health Q2 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve
Nexstar Media Group Q2 Earnings Call Highlights
Nexstar Media Group (NASDAQ:NXST) reported record second-quarter results as revenue nearly reached $2 billion, aided by its acquisition of
CPI Card Group Q2 Earnings Call Highlights
Key Points
- Interested in CPI Card Group Inc.? Here are five stocks we like better.
- CPI Card Group raised its 2026 outlook for revenue growth to high single digits to low double digits and free
Pulse Biosciences Q2 Earnings Call Highlights
Key Points
- Interested in Pulse Biosciences, Inc? Here are five stocks we like better.
- Pulse Biosciences accelerated its atrial fibrillation program: The U.S. NANOPULSE-AF pivotal trial surpassed
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Q2 Earnings Call Highlights
Key Points
- Interested in Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München? Here are five stocks we like better.
- Munich Re remains on track for its 2026 profit target
New Strong Buy Stocks for August 7th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
EuroDry Ltd. EDRY: This ocean-going transportation services company has seen the Zacks Consensus Estimate for its next year
Peloton Interactive Q4 Earnings Call Highlights
Key Points
- Interested in Peloton Interactive, Inc.? Here are five stocks we like better.
- Peloton completed fiscal 2026 profitably, reporting its first full year of positive net income and
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
The American Century U.S. Quality Value ETF (VALQ) made its debut on 01/11/2018, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - All Cap Value category of
Bear of the Day: Builders FirstSource (BLDR)
Builders FirstSource, Inc. BLDR is caught in a four-year housing recession and is waiting for it to end. Earnings of this Zacks #5 (Strong Sell) are expected to fall another 54.3% this year.
Relmada Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Relmada Therapeutics, Inc.? Here are five stocks we like better.
- NDV-01 manufacturing is Relmada’s immediate priority as it targets an investigational new drug
REGENXBIO Q2 Earnings Call Highlights
Key Points
- Interested in REGENXBIO Inc.? Here are five stocks we like better.
- RGX-202 Duchenne program advanced toward filing: REGENXBIO completed enrollment and dosing in its confirmatory